Investors Q and A, page-24

RudiV, you are correct the providers need to see the benefit, the return and an ability to dial this into the current work flows at scale to make it worthwhile. Additionally as you can only cliam RPM once per patient, if its a patient with co-morbidities, CHF, Diabeties, COPD then the Doc has to choose which therapy to apply for through RPM, respiratory is new to RPM relative to others . ADR need to invest in educaion the providers on the tech, patient selection and how to fit this into their workflow. This aint simple and not something you just pick up an run with. Additionally ADR need to convince that using respiratrory as he primary RPM therapy is teh best and most sustained generatimg the most return. That takes a focused trained sales force who can compliantly talk tech, therapy and reimbursememt. Clawback penalties and fines is what the Docs fear most. I would not leave that to a distributor. For them its too much effort for unproven return.

Link to ERP, ideally yes and or ADR need that ecosystem platform they previously talked about. One product companies with a single data stream are a nightmare for US systems led medicine. Docs want all teh data for a patient from all devices in one palce. Thats why the ecosystem they "promised" in teh 2021 raise was so exciting and why its so disappointing teh CEO has seemingly ditched it in favour of more and more sensors whicj yup are easier to develop and deliver, but to date, no one is buying, as far as we know- tumble weed communication on orders, sales and revenue-or revenue.

ADR needs something and someone new. Those in Leadership need to look inward and be honest about competancy. If our pommie friends ex PM Liz Truss had the courage to admit failure and step aside other should at least look in the mirror and ask teh question.